TipRanksStock Market NewsJonesTrading Thinks Monopar Therapeutics Inc’s Stock is Going to Recover

JonesTrading Thinks Monopar Therapeutics Inc’s Stock is Going to Recover

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Monopar Therapeutics Inc (MNPRResearch Report), with a price target of $33.00. The company’s shares closed last Tuesday at $3.82, close to its 52-week low of $3.70.

According to TipRanks.com, Roy is a 5-star analyst with an average return of 21.3% and a 36.3% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Monopar Therapeutics Inc with a $17.67 average price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $17.01 and a one-year low of $3.70. Currently, Monopar Therapeutics Inc has an average volume of 75.96K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Read More on MNPR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More